Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 368

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 368
---
6.20 | ) |     | $ |     (0.78 | ) |

| (1) | Included within weighted average common shares outstanding for the years ended December 31, 2024 and 2023                                                                                                                                          
 are 3,181,839 and 2,102,412, respectively, common shares issuable upon the exercise of penny warrants. Per ASC 260, Earnings Per Share, the warrants are exercisable at any time for nominal consideration, and as such, the shares are considered 
 outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.                                                                                                                               |

The Company’s potentially dilutive securities, which consist of stock options and convertible preferred stock, have been excluded from the computation of diluted net loss per share because including them would have had an anti-dilutive impact. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following common stock equivalents, presented based on amounts outstanding at each period end, have been excluded from the calculation of diluted net loss per share because including them would have an antidilutive effect (in thousands):

|                                        |     |     | December 31, 
         2024 |     |     | December 31, 
         2023 |
|:---------------------------------------|:----|:----|-------------:|:----|:----|-------------:|
| Redeemable convertible preferred stock |     |     |       78,071 |     |     |       51,405 |
| Restricted stock - unvested            |     |     |          190 |     |     |          193 |
| Common stock warrants                  |     |     |           98 |     |     |          100 |
| Stock options                          |     |     |       12,749 |     |     |        3,582 |
| Total Common Stock Equivalents         |     |     |       91,108 |     |     |       55,280 |

F-27

LB Pharmaceuticals Inc Notes to Financial Statements 10. Stock-Based Compensation The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives consist primarily of stock options and restricted stock grants. In 2017, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan authorized the